NV Organon, a subsidiary of Merck & Co fails to secure patent in India for female contraceptive kit.
As per reports, NV Organon, a subsidiary of US-based Merck & Co ,one of the largest pharma companies in the world has failed to secure a patent in India for its invention on a female contraceptive kit. The kit, which comprises a vaginal ring, is used in cyclical dosage and has a reminder system. Organon has a similar product under trade name NuvaRing (etonogestrel/ethinyl estradiol vaginal ring), which received initial US approval in 2001 and has been marketed worldwide. That Us patent expires in 2018. Organon followed with another patent in 2006 `Regimens for Oral Monophasic Contraceptives'.
This patent claims: A method of human female contraception which comprises: (i) administering a monophasic oral contraceptive dosage unit once a day starting on numerical date ‘m+4’ of a month continuously until numerical date ‘m’ of the following month; and (ii) not administering the monophasic oral contraceptive dosage unit in the numerical dates between ‘m’ and ‘m+4’; wherein ‘m’ is a numerical date of a month from 1-24 and wherein the method is repeatedly carried out for at least two cycles.